This site uses cookies for analytics and to improve your experience. By clicking Accept, you consent to our use of cookies. Learn more in our privacy policy.

Subscribe
Watch

Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Orum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies. Source: Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Globe News Wire Avatar

by

Globe News Wire
1 minute

Read Time

Orum receives FDA clearance for ORM-1153, advancing its novel CD123-GSPT1 degrader-antibody conjugate toward Phase 1 in hematologic malignancies.

Source: Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate

Tags: , ,

Previous Post

Next Post

Latest News

View All

About the Author

We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

You May Have Missed

View All